Real-World Outcomes of Carotid Artery Stenting in Symptomatic and Asymptomatic Patients With Carotid Artery Stenosis

无症状的 医学 狭窄 心脏病学 颈动脉 内科学 放射科 动脉
作者
Kazutaka Uchida,Fumihiro Sakakibara,Nobuyuki Sakai,Koji Iihara,Hirotoshi Imamura,Akira Ishii,Yuji Matsumaru,Chiaki Sakai,Tetsu Satow,Kiyofumi Yamada,Manabu Shirakawa,Shinichi Yoshimura
出处
期刊:Jacc-cardiovascular Interventions [Elsevier]
卷期号:17 (9): 1148-1159 被引量:6
标识
DOI:10.1016/j.jcin.2024.03.014
摘要

The effectiveness and safety of carotid artery stenting (CAS) are comparable to those of carotid endarterectomy in both symptomatic and asymptomatic patients with carotid artery stenosis, but real-world outcomes are not well-known. The purpose of this study was to investigate the real-world clinical outcomes of CAS in symptomatic and asymptomatic patients with carotid artery stenosis. We conducted a nationwide retrospective registry study of 156 centers between January 2015 and December 2019. We enrolled consecutive patients with CAS managed by certified specialists from the Japanese Society of Neuroendovascular Therapy. Outcomes between symptomatic and asymptomatic patients were compared. The primary outcome was a composite of ischemic stroke and all-cause death at 30 days after CAS. Secondary outcomes were ischemic stroke, all-cause death, intracranial hemorrhage (ICH), and procedural complications. We analyzed 9,792 patients (symptomatic, n = 5,351; asymptomatic, n = 4,441). The mean age was 73.5 years, and men were dominant (86.4%). Embolism protection devices were used in 99% of patients. The primary outcome was not significantly different between the symptomatic and asymptomatic groups (120 [2.2%] vs 65 [1.5%]; adjusted OR: 1.30; 95% CI: 0.92-1.83). The incidences of symptomatic ICH, any ICH, acute in-stent occlusion, and hyperperfusion syndrome were significantly more prevalent in the symptomatic group (47 [0.9%] vs 8 [0.2%], aOR: 4.41 [95% CI: 1.68-11.6]; 73 [1.4%] vs 12 [0.3%], aOR: 3.56 [95% CI: 1.71-7.39]; 45 [0.8%] vs 19 [0.4%], aOR: 2.18 [95% CI: 1.08-4.40]; and 102 [1.9%] vs 36 [0.8%], aOR: 1.78 [95% CI: 1.17-2.71], respectively). Other secondary outcomes were not significantly different between the 2 groups. The complication rate after specialist-involved CAS at 30 days was low in real-world practice.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
大个应助科研通管家采纳,获得10
刚刚
刚刚
1秒前
1秒前
机灵筮发布了新的文献求助10
1秒前
1秒前
WeiPaiHWuFXZ完成签到,获得积分10
1秒前
2秒前
2秒前
邱之神者完成签到,获得积分10
2秒前
量子星尘发布了新的文献求助10
3秒前
漂亮傥完成签到,获得积分10
3秒前
脑洞疼应助Ausir采纳,获得10
3秒前
Owen应助xueshu采纳,获得10
4秒前
4秒前
4秒前
haozai完成签到,获得积分10
5秒前
xueluxin完成签到 ,获得积分10
5秒前
cc举报受伤的千凝求助涉嫌违规
5秒前
万能图书馆应助蓝天采纳,获得10
6秒前
6秒前
充电宝应助蓝天采纳,获得10
6秒前
研友_VZG7GZ应助蓝天采纳,获得10
6秒前
华仔应助蓝天采纳,获得10
6秒前
NexusExplorer应助蓝天采纳,获得10
6秒前
科目三应助蓝天采纳,获得10
6秒前
科研通AI2S应助蓝天采纳,获得10
6秒前
科研通AI6应助蓝天采纳,获得10
6秒前
情怀应助蓝天采纳,获得10
6秒前
咔咔完成签到,获得积分10
6秒前
Owen应助jinyu采纳,获得30
7秒前
胡佳庆完成签到,获得积分20
7秒前
云来如梦完成签到 ,获得积分10
7秒前
8秒前
在水一方应助Sieg采纳,获得10
8秒前
蘇尼Ai发布了新的文献求助10
8秒前
Ljh发布了新的文献求助10
9秒前
Allen完成签到 ,获得积分10
9秒前
hhh发布了新的文献求助10
9秒前
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
2025-2031全球及中国金刚石触媒粉行业研究及十五五规划分析报告 9000
Encyclopedia of the Human Brain Second Edition 8000
The Cambridge History of China: Volume 4, Sui and T'ang China, 589–906 AD, Part Two 1000
The Composition and Relative Chronology of Dynasties 16 and 17 in Egypt 1000
Translanguaging in Action in English-Medium Classrooms: A Resource Book for Teachers 700
Real World Research, 5th Edition 680
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 计算机科学 有机化学 物理 生物化学 纳米技术 复合材料 内科学 化学工程 人工智能 催化作用 遗传学 数学 基因 量子力学 物理化学
热门帖子
关注 科研通微信公众号,转发送积分 5684488
求助须知:如何正确求助?哪些是违规求助? 5036727
关于积分的说明 15184287
捐赠科研通 4843754
什么是DOI,文献DOI怎么找? 2596869
邀请新用户注册赠送积分活动 1549511
关于科研通互助平台的介绍 1508027